Abcuro
First-in-Class immuno-oncology agent complementary with existing therapies, and autoimmune drug for inclusion body myositis.
Abcuro is pursuing a single Ab discovery campaign to yield two independent antibody therapeutic programs:
1. Anti-target depleter (autoimmunity)
2. Anti-target neutralizer (immuno-oncology)
